Methylmalonic Acidemia - Epidemiology Forecast - 2032

January 2022 | 60 pages | ID: M157AFCC46CBEN
DelveInsight

Abstracts

This report can be delivered to the clients within 5-7 Business Days

DelveInsight's 'Methylmalonic Acidemia - Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Methylmalonic Acidemia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

• The United States
• EU5 (Germany, France, Italy, Spain, and the United Kingdom)
• Japan

Study Period: 2019-2032

Methylmalonic Acidemia Understanding

The DelveInsight Methylmalonic Acidemia epidemiology report gives a thorough understanding of the Methylmalonic Acidemia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Methylmalonic Acidemia in the US, Europe, and Japan. The report covers the detailed information of the Methylmalonic Acidemia epidemiology scenario in seven major countries (US, EU5, and Japan).

Methylmalonic Acidemia Epidemiology Perspective by DelveInsight

The Methylmalonic Acidemia epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Methylmalonic Acidemia epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Methylmalonic Acidemia epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2019 to 2032. It also helps recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Methylmalonic Acidemia Detailed Epidemiology Segmentation

The Methylmalonic Acidemia epidemiology covered in the report provides historical as well as forecasted Methylmalonic Acidemia epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.

The DelveInsight Methylmalonic Acidemia report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

• The Methylmalonic Acidemia report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
• The Methylmalonic Acidemia Epidemiology Report and Model provide an overview of the global trends of Methylmalonic Acidemia in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
• The report provides insight into the historical and forecasted patient pool of Methylmalonic Acidemia in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
• The report helps recognize the growth opportunities in the 7MM for the patient population
• The report assesses the disease risk and burden and highlights the unmet needs of Methylmalonic Acidemia
• The report provides the segmentation of the Methylmalonic Acidemia epidemiology

Report Highlights

• 11-year Forecast of Methylmalonic Acidemia epidemiology
• 7MM Coverage
• Prevalent and Diagnosed Cases of Methylmalonic Acidemia
• Cases of Methylmalonic Acidemia by Mutation Types
• Methylmalonic Acidemia Cases associated with Clinical Manifestations

KOL views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

• What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Methylmalonic Acidemia?
• What are the key findings pertaining to the Methylmalonic Acidemia epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2019-2032)?
• What would be the total number of patients of Methylmalonic Acidemia across the 7MM during the forecast period (2019-2032)?
• Among the EU5 countries, which country will have the highest number of patients during the forecast period (2019-2032)?
• At what CAGR the patient population is expected to grow in 7MM during the forecast period (2019-2032)?
• What is the disease risk, burden and unmet needs of Methylmalonic Acidemia?
• What are the currently available treatments of Methylmalonic Acidemia?

Reasons to buy

The Methylmalonic Acidemia Epidemiology report will allow the user to -

• Develop business strategies by understanding the trends shaping and driving the global Methylmalonic Acidemia market
• Quantify patient populations in the global Methylmalonic Acidemia market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Methylmalonic Acidemia therapeutics in each of the markets covered
• Understand the magnitude of Methylmalonic Acidemia population by its epidemiology
• The Methylmalonic Acidemia Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

• Patient Segmentation
• Disease Risk & Burden
• Risk of disease by the segmentation
• Factors driving growth in a specific patient population

Contents

1. KEY INSIGHTS

2. EXECUTIVE SUMMARY OF METHYLMALONIC ACIDEMIA

3. METHYLMALONIC ACIDEMIA: DISEASE BACKGROUND AND OVERVIEW

3.1. Introduction
3.2. Sign and Symptoms
3.3. Pathophysiology
3.4. Risk Factors
3.5. Diagnosis

4. PATIENT JOURNEY

5. EPIDEMIOLOGY AND PATIENT POPULATION

5.1. Epidemiology Key Findings
5.2. Assumptions and Rationale: 7MM
5.3. Epidemiology Scenario: 7MM
  5.3.1. Methylmalonic Acidemia Epidemiology Scenario in the 7MM (2019- 2032)
5.4. United States Epidemiology
  5.4.1. Methylmalonic Acidemia Epidemiology Scenario in the United States (2019- 2032)
5.5. EU-5 Country-wise Epidemiology
  5.5.1. Germany Epidemiology
    5.5.1.1. Methylmalonic Acidemia Epidemiology Scenario in Germany (2019- 2032)
  5.5.2. France Epidemiology
    5.5.2.1. Methylmalonic Acidemia Epidemiology Scenario in France (2019- 2032)
  5.5.3. Italy Epidemiology
    5.5.3.1. Methylmalonic Acidemia Epidemiology Scenario in Italy (2019- 2032)
  5.5.4. Spain Epidemiology
    5.5.4.1. Methylmalonic Acidemia Epidemiology Scenario in Spain (2019- 2032)
  5.5.5. United Kingdom Epidemiology
    5.5.5.1. Methylmalonic Acidemia Epidemiology Scenario in the United Kingdom (2019-2032)
5.6. Japan Epidemiology
  5.6.1. Methylmalonic Acidemia Epidemiology Scenario in Japan (2019- 2032)

6. TREATMENT ALGORITHM, CURRENT TREATMENT, AND MEDICAL PRACTICES

6.1. Methylmalonic Acidemia Treatment and Management
6.2. Methylmalonic Acidemia Treatment Algorithm

7. KOL VIEWS

8. UNMET NEEDS

9. APPENDIX

9.1. Bibliography
9.2. Report Methodology

10. DELVEINSIGHT CAPABILITIES

11. DISCLAIMER

12. ABOUT DELVEINSIGHT

*The table of contents is not exhaustive; will be provided in the final report

List Of Tables

LIST OF TABLES

List of Table:
Table 1: Methylmalonic Acidemia Epidemiology in 7MM (2019-2032)
Table 2: Methylmalonic Acidemia Diagnosed and Treatable Cases in 7MM (2019-2032)
Table 3: Methylmalonic Acidemia Epidemiology in the United States (2019-2032)
Table 4: Methylmalonic Acidemia Diagnosed and Treatable Cases in the United States (2019-2032)
Table 5: Methylmalonic Acidemia Epidemiology in Germany (2019-2032)
Table 6: Methylmalonic Acidemia Diagnosed and Treatable Cases in Germany (2019-2032)
Table 7: Methylmalonic Acidemia Epidemiology in France (2019-2032)
Table 8: Methylmalonic Acidemia Diagnosed and Treatable Cases in France (2019-2032)
Table 9: Methylmalonic Acidemia Epidemiology in Italy (2019-2032)
Table 10: Methylmalonic Acidemia Diagnosed and Treatable Cases in Italy (2019-2032)
Table 11: Methylmalonic Acidemia Epidemiology in Spain (2019-2032)
Table 12: Methylmalonic Acidemia Diagnosed and Treatable Cases in Spain (2019-2032)
Table 13: Methylmalonic Acidemia Epidemiology in the United Kingdom (2019-2032)
Table 14: Methylmalonic Acidemia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Table 15: Methylmalonic Acidemia Epidemiology in Japan (2019-2032)
Table 16: Methylmalonic Acidemia Diagnosed and Treatable Cases in Japan (2019-2032)

List Of Figures

LIST OF FIGURES

List of Figures
Figure 1 Methylmalonic Acidemia Epidemiology in 7MM (2019-2032)
Figure 2 Methylmalonic Acidemia Diagnosed and Treatable Cases in 7MM (2019-2032)
Figure 3 Methylmalonic Acidemia Epidemiology in the United States (2019-2032)
Figure 4 Methylmalonic Acidemia Diagnosed and Treatable Cases in the United States (2019-2032)
Figure 5 Methylmalonic Acidemia Epidemiology in Germany (2019-2032)
Figure 6 Methylmalonic Acidemia Diagnosed and Treatable Cases in Germany (2019-2032)
Figure 7 Methylmalonic Acidemia Epidemiology in France (2019-2032)
Figure 8 Methylmalonic Acidemia Diagnosed and Treatable Cases in France (2019-2032)
Figure 9 Methylmalonic Acidemia Epidemiology in Italy (2019-2032)
Figure 10 Methylmalonic Acidemia Diagnosed and Treatable Cases in Italy (2019-2032)
Figure 11 Methylmalonic Acidemia Epidemiology in Spain (2019-2032)
Figure 12 Methylmalonic Acidemia Diagnosed and Treatable Cases in Spain (2019-2032)
Figure 13 Methylmalonic Acidemia Epidemiology in the United Kingdom (2019-2032)
Figure 14 Methylmalonic Acidemia Diagnosed and Treatable Cases in the United Kingdom (2019-2032)
Figure 15 Methylmalonic Acidemia Epidemiology in Japan (2019-2032)
Figure 16 Methylmalonic Acidemia Diagnosed and Treatable Cases in Japan (2019-2032)
*The table of contents is not exhaustive; will be provided in the final report